Last reviewed · How we verify
NDec - oral decitabine-tetrahydrouridine
At a glance
| Generic name | NDec - oral decitabine-tetrahydrouridine |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Research Study Investigating How Well NDec Works in People With Sickle Cell Disease (PHASE2)
- A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NDec - oral decitabine-tetrahydrouridine CI brief — competitive landscape report
- NDec - oral decitabine-tetrahydrouridine updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI